WHA Committees Approve Plans On Antimicrobial Resistance, Vaccines, Innovation

Today, member states in committee at the World Health Assembly adopted the first global plan of action to address the issue of antimicrobial resistance, and a global plan of action on vaccines. In addition, a mechanism on public health, innovation and intellectual property was postponed until 2022, and a deadline for its evaluation moved to 2018.

An Interview With WIPO Director General Francis Gurry On The New Lisbon Act For GIs

Members of the Lisbon Agreement for the Protection of Appellations of Origin and their International Registration on 20 May agreed on a new Act of the agreement, extending protection previously granted only to appellations of origins to geographical indications. The World Intellectual Property Organization is responsible for this agreement. After the signing ceremony at WIPO, Intellectual Property Watch sat down with WIPO Director General Francis Gurry to discuss the new Act.

WHA 68: Experts Discuss Delinking Drug R&D Costs From Pricing To Make Them Affordable

The problem of drug prices eating up national health budgets has been coming up at the annual World Health Assembly. Last week, a panel of experts discussed the merits of lowering those prices by delinking research and development costs from pricing.

WHO Advances R&D Financing Effort; Global R&D Observatory To Launch In January

World Health Organization members in committee this week took note of a report by the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), which was set up to find ways to fund research on diseases afflicting poor populations which have little market incentive for the private sector. The report included a proposal for a voluntary pooled fund that would focus on the development of effective and affordable health technologies for such neglected diseases.

Review Of WHO Mechanism To Fight Substandard Medicines Postponed Until 2017

World Health Organization delegates today agreed in committee to postpone until 2017 the review of a mechanism that had been set up to help countries deal with substandard and fake medicines.

Switch to our mobile site